Proprotein convertase subtilisin/kexin type 9 inhibitors on the horns of a dilemma: which lipoprotein we should primarily target - low-density lipoprotein or lipoprotein(a)?

Affiliations

Comment

Andreas S Papazoglou et al. J Cardiovasc Med (Hagerstown). 2022.

. 2022 Sep 1;23(9):635-636.

doi: 10.2459/JCM.0000000000001313.

No abstract available

Comment on

Proprotein convertase subtilisin/kexin type 9 inhibitors treatment in dyslipidemic patients: a real world prescription.
Derosa G, Maffioli P, D'Angelo A, Girola A, Colombo E, Fiorenza AM, Macias JJC, Sanchez CL, Raddino R, Pasini GF, Triggiani M, Maresca AM, Tandurella N, Guasti L. Derosa G, et al. J Cardiovasc Med (Hagerstown). 2022 Feb 1;23(2):91-97. doi: 10.2459/JCM.0000000000001237. J Cardiovasc Med (Hagerstown). 2022. PMID: 34690259

1. Derosa G, Maffioli P, D’Angelo A, et al. Proprotein convertase subtilisin/kexin type 9 inhibitors treatment in dyslipidemic patients: a real world prescription. J Cardiovasc Med (Hagerstown) 2022; 23:91–97.
1. Dicembrini I, Giannini S, Ragghianti B, Mannucci E, Monami M. Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Endocrinol Invest 2019; 42:1029–1039.
1. Deedwania P, Murphy SA, Scheen A, et al. Efficacy and safety of PCSK9 inhibition with evolocumab in reducing cardiovascular events in patients with metabolic syndrome receiving statin therapy: secondary analysis from the FOURIER Randomized Clinical Trial. JAMA Cardiol 2021; 6:139–147.
1. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372:1489–1499.
1. Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med 2017; 376:1527–1539.